Akebia Therapeutics Inc. (AKBA) Stock: A Closer Look at the Analyst Ratings
Additionally, the 36-month beta value for AKBA is 0.88. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0
Additionally, the 36-month beta value for AKBA is 0.88. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0
AKBA has 36-month beta value of 0.86. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 0 as “overweight,”
The stock of Akebia Therapeutics Inc. (AKBA) has seen a -10.29% decrease in the past week, with a 18.83% gain in the past month, and
In the past week, AKBA stock has gone up by 16.93%, with a monthly gain of 63.70% and a quarterly surge of 84.17%. The volatility
The stock has a 36-month beta value of 0.80. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 0 as
The stock of Akebia Therapeutics Inc. (AKBA) has gone up by 15.65% for the week, with a 11.11% rise in the past month and a
© 2024, Fueled by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.